Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$28.95
Change (%) Stock is Down 0.5 (1.70%)
Volume429,115
Data as of 04/28/17 4:00 p.m. ET
Refresh quote
Recent Events
Webcast
GBT at the 2016 American Society of Hematology (ASH) Annual Meeting (Replay)
12/05/16 at 12:15 p.m. PT
ASH 2016 Poster: Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor
ASH 2016 Poster: The 9-Item Sickle Cell Disease Severity Measure (SCDSM): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
ASH 2016 Poster: Absorption, Metabolism, and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects
Corporate Presentation
Download Documentation Corporate Presentation (March 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
03/29/17Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the 16th Annual Needham Healthcare Conference in New York, NY on Wednesday, April 5 at 12:10 p.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopharm... 
Printer Friendly Version
03/13/17Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the fourth quarter and year ended December 31, 2016. "2016 was a year of consistent execution and rapid advancement across both of our GBT440 clinical programs designed to treat diseases where the patient communities are greatly underserved. This was highlighted by coming to agreement with the FDA on the design of our p... 
Printer Friendly Version
03/01/17Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the following investor conferences in March: Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 8:40 a.m. Eastern Time (ET); and The 29th Annual ROTH Conference in Dana Point, CA on Tuesday, March 14, 2017 at 4:30 p.m. Pacific Time (PT). The presentations will be webcast live and ava... 
Printer Friendly Version
02/27/17Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the closing of its previously announced underwritten public offering of 5,867,347 shares of its common stock at a price to the public of $24.50 per share, which includes 765,306 additional shares of ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.